Chronic Obstructive Pulmonary Disease (COPD): Nursing Study Guide

Chronic obstructive pulmonary disease (COPD) is one of the most common chronic respiratory disorders nurses will manage at the bedside and on the NCLEX. This guide reviews the pathophysiology, two main phenotypes, diagnostic criteria, GOLD staging, pharmacologic and non-pharmacologic therapy, exacerbation management, and high-yield nursing priorities.

What Is COPD?

• A preventable and treatable disease characterized by persistent respiratory symptoms and airflow limitation.
• Airflow limitation is persistent and progressive, caused by chronic inflammation from noxious particles or gases.
• Includes two main conditions: chronic bronchitis and emphysema. Most patients have features of both.

Chronic Bronchitis vs Emphysema

Chronic Bronchitis ("Blue Bloater")

• Pathophysiology: Inflammation and mucus gland hyperplasia.
• Definition: Cough with sputum ≥3 months for 2 consecutive years.
• Appearance: Cyanotic, overweight, peripheral edema.
• Breath sounds: Coarse crackles, wheezes.

Emphysema ("Pink Puffer")

• Pathophysiology: Alveolar wall destruction with loss of elastic recoil.
• Definition: Permanent enlargement of air spaces.
• Appearance: Thin, barrel chest, accessory muscle use.
• Breath sounds: Diminished breath sounds, prolonged expiration.

Risk Factors

• Smoking — the most important risk factor (80–90% of cases).
• Alpha-1 antitrypsin deficiency — genetic cause of early-onset emphysema.
• Environmental exposures: biomass fuel smoke, occupational dusts, air pollution.
• Older age and significant respiratory infections in childhood.

Pathophysiology

• Inhaled irritants trigger chronic inflammation of the airways and lung parenchyma.
• This leads to small airway narrowing and parenchymal destruction.
• The result is expiratory airflow limitation and air trapping.
• Impaired gas exchange produces hypoxemia and eventually hypercapnia.

Clinical Presentation

Symptoms

• Dyspnea — progressive, persistent, worse with exercise.
• Chronic cough — intermittent or daily.
• Sputum production — variable amount and consistency.
• Wheezing, fatigue, and weight loss in advanced disease.

Exam Findings

• Barrel chest from hyperinflation.
• Prolonged expiration and accessory muscle use.
• Tripod position and pursed-lip breathing.
• Distant breath sounds with wheezes or crackles.

mMRC Dyspnea Scale

The modified Medical Research Council (mMRC) scale is a patient-reported tool grading breathlessness 0–4 based on impact on daily activity. It is recommended in GOLD guidelines for symptom assessment.

• Grade 0: Breathless only with strenuous exercise — minimal impact.
• Grade 1: Short of breath when hurrying on level ground or walking up a slight hill — early functional limitation.
• Grade 2: Walks slower than peers or stops to catch breath on level ground — significant mobility impact.
• Grade 3: Stops for breath after ~100 meters or a few minutes on level ground — severe limitation.
• Grade 4: Too breathless to leave the house or breathless when dressing — end-stage, housebound.

Diagnostic Tests

• Spirometry (gold standard): FEV1/FVC ratio <0.70 confirms persistent airflow limitation. Severity is graded by FEV1 % predicted.
• Chest X-ray: Used to rule out other causes. COPD features include a flattened diaphragm, hyperinflation, and bullae in advanced disease.
• Arterial blood gas (ABG): May show hypoxemia and hypercapnia in advanced disease.

COPD Severity — GOLD Stages

• GOLD 1 (Mild): FEV1 ≥80% predicted.
• GOLD 2 (Moderate): FEV1 50–79% predicted.
• GOLD 3 (Severe): FEV1 30–49% predicted.
• GOLD 4 (Very Severe): FEV1 <30% predicted.

GOLD Groups (Symptom & Exacerbation Risk)

• Group A: Low risk, few symptoms (mMRC 0–1).
• Group B: Low risk, more symptoms (mMRC ≥2).
• Group E: High risk — ≥2 exacerbations or ≥1 hospitalization per year.

Pharmacologic Management

• Short-acting beta agonists (SABA) — e.g., albuterol; rescue for acute symptoms.
• Short-acting anticholinergics (SAMA) — e.g., ipratropium; often combined with albuterol.
• Long-acting beta agonists (LABA) — e.g., salmeterol; 12-hour maintenance, not for acute relief.
• Long-acting anticholinergics (LAMA) — e.g., tiotropium; 24-hour first-line maintenance for stable COPD.
• Inhaled corticosteroids (ICS) — e.g., fluticasone; added for frequent exacerbations or elevated eosinophils.
• Combination inhalers (LABA/LAMA or LABA/ICS) provide synergistic effects and improve adherence.

Stepwise Treatment (GOLD Guidelines)

• Group A: A bronchodilator (SABA, LABA, or LAMA).
• Group B: LABA + LAMA combination.
• Group E: LABA + LAMA; consider ICS if eosinophils ≥300.
• Escalate therapy if symptoms persist.
• Triple therapy (LABA + LAMA + ICS) for frequent exacerbations.

Non-Pharmacologic Management

• Smoking cessation — the single most effective intervention.
• Pulmonary rehabilitation — improves exercise tolerance and symptoms.
• Vaccinations — influenza and pneumococcus reduce exacerbations.
• Oxygen therapy — improves survival in hypoxemic patients.

Oxygen Therapy Indications

• Resting PaO2 ≤55 mmHg or SpO2 ≤88%.
• PaO2 56–59 mmHg with cor pulmonale or polycythemia.
• Goal: maintain SpO2 ≥90% at rest, during sleep, and with exertion.

Acute Exacerbation of COPD

An acute worsening of respiratory symptoms requiring additional therapy.

Common Triggers

• Respiratory infections (viral or bacterial) — most common.
• Air pollution and environmental irritants.
• Non-adherence to maintenance therapy.

Signs of Exacerbation

• Increased dyspnea, wheezing, and cough.
• Change in sputum color, volume, or consistency; purulent sputum suggests bacterial infection.
• Tachypnea, tachycardia, accessory muscle use.
• Confusion — indicates hypercapnia.

Management

• Increase bronchodilator frequency (SABA + SAMA).
• Systemic corticosteroids — prednisone 40 mg daily for 5 days.
• Antibiotics if sputum is purulent — amoxicillin-clavulanate or doxycycline.
• Controlled oxygen to maintain SpO2 88–92% (avoid high-flow oxygen).
• Non-invasive ventilation (BiPAP) for hypercapnic respiratory failure.

Nursing Care

Assessment

• Monitor respiratory rate, depth, and effort.
• Assess breath sounds for wheezes or diminished sounds.
• Measure SpO2; titrate to 88–92%.
• Watch for accessory muscle use and altered mental status.
• Monitor sputum color and consistency.

Interventions

• Position in high-Fowler's or tripod position.
• Administer bronchodilators and corticosteroids as prescribed.
• Teach pursed-lip and diaphragmatic breathing.
• Encourage effective coughing and hydration.
• Provide small, frequent meals to reduce oxygen demand.
• Pace activities and promote energy conservation.

Patient Teaching

• Use bronchodilators first, then inhaled corticosteroids.
• Rinse mouth after ICS to prevent oral thrush.
• Distinguish rescue vs maintenance inhalers.
• Use a spacer with MDI for improved drug delivery.
• Practice pursed-lip breathing to prevent airway collapse.
• Plan activities with rest periods.
• Report increased dyspnea, sputum changes, fever, or leg swelling.
• Seek immediate care for confusion or drowsiness.

Common NCLEX Traps

• Confusing chronic bronchitis ("Blue Bloater") with emphysema ("Pink Puffer").
• Giving high-flow oxygen to COPD patients — risks loss of hypoxic drive.
• Forgetting that spirometry confirms diagnosis, not chest X-ray.
• Missing that FEV1/FVC <0.70 confirms obstruction.
• Using albuterol alone for maintenance when LABA/LAMA are indicated.
• Not recognizing smoking cessation as the most effective intervention.
• Forgetting to rinse the mouth after ICS use.
• Missing that BiPAP is first-line for hypercapnic respiratory failure.

Key Takeaways

• COPD has two phenotypes: chronic bronchitis ("Blue Bloater") from inflammation/mucus and emphysema ("Pink Puffer") from alveolar destruction.
• Diagnosis is confirmed by spirometry with FEV1/FVC <0.70; severity is staged by FEV1 % predicted (GOLD 1–4).
• LABA/LAMA bronchodilators are the cornerstone of maintenance therapy; ICS is added for frequent exacerbations or high eosinophils.
• Smoking cessation is the single most effective intervention to slow disease progression.
• Acute exacerbations: increase bronchodilators, prednisone 40 mg × 5 days, antibiotics if purulent, and oxygen titrated to SpO2 88–92%.
• Use BiPAP for hypercapnic respiratory failure; avoid high-flow oxygen that may suppress the hypoxic drive.